• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

    11/14/24 12:21:08 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KRRO alert in real time by email
    SC 13G/A 1 eventide_korro-sc13ga.htm SC 13G/A

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

    Korro Bio, Inc.

    (Name of Issuer – as specified in its charter)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    500946108

    (CUSIP Number)

    September 30, 2024

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    þ       Rule 13d-1(b)

    ¨        Rule 13d-1(c)

    ¨        Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    1

    NAME OF REPORTING PERSON

    Eventide Asset Management, LLC

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    ¨ (a)

    ¨ (b)

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

    391,166

     

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    391,166

     

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    391,166

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.21%

     

    12

    TYPE OF REPORTING PERSON

    IA

           

     

     
     

     

    1

    NAME OF REPORTING PERSON

    Finny Kuruvilla, M.D. Ph. D.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    ¨ (a)

    ¨ (b)

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

    0

     

    6

    SHARED VOTING POWER

    391,166

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    391,166

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    391,166

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.21%

     

    12

    TYPE OF REPORTING PERSON

    IN;HC

           

     

     
     

     

    1

    NAME OF REPORTING PERSON

    Robin C. John

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    ¨ (a)

    ¨ (b)

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

    0

     

    6

    SHARED VOTING POWER

    391,166

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    391,166

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    391,166

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.21%

     

    12

    TYPE OF REPORTING PERSON

    IN;HC

           

     

     
     

    Item 1. (a) Name of Issuer:

    Korro Bio, Inc. (the “Issuer”)

    (b) Address of Issuer’s Principal Executive Offices:

    One Kendall Square Building 600-700, Suite 6-401, Cambridge, MA 02139

    Item 2. (a) Name of Persons Filing:

    (i) Eventide Asset Management, LLC (“Eventide”)

    (ii) Finny Kuruvilla, M.D., Ph.D. (“Kuruvilla”)

    (iii) Robin C. John (“John”)

    (b). Address of Principal Business Office or, if none, Residence:

    Eventide, Kuruvilla and John:

    One International Place, Suite 4210

    Boston, Massachusetts 02110

    (c). Citizenship or Place of Organization:

    Eventide: Delaware

    Kuruvilla: United States

    John: United States

    (d). Title of Class of Securities:

    Common Stock, par value $0.001 per share

     

    (e). CUSIP Number:

    500946108

    Item 3. If this statement is filed pursuant to sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

    (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

    (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

    (e) [x] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E);

    (f) [ ] An employee benefit plan or endowment fund in accordance with section 240.13d- 1(b)(1)(ii)(F);

    (g) [x] A parent holding company or control person in accordance with section 240.13d- 1(b)(1)(ii)(G);

    (h) [ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance

    Act (12 U.S.C. 1813);

     
     

    (i) [ ] A church plan that is excluded from the definition of an investment company under

    section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j) [ ] A non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J);

    (k) [ ] A group, in accordance with section 240.13d-1(b)(1) (ii)(K).

    If filing as a non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

    Item 4. Ownership:

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

    (a). Amount beneficially owned:

    (i) Eventide: 391,166

    (ii) Kuruvilla: 391,166

    (iii) John: 391,166

    (b). Percent of class:

    (i) Eventide: 4.21%

    (ii) Kuruvilla: 4.21%

    (iii) John: 4.21%

    (c). Number of shares as to which the person has:

    (i)        Sole power to vote or to direct the vote:

    (1) Eventide: 391,166

    (2) Kuruvilla: 0

    (3) John: 0

    (ii)        Shared power to vote or to direct the vote:

     

    (1) Eventide: 0

    (2) Kuruvilla: 391,166

    (3) John: 391,166

    (iii) Sole power to dispose or to direct the disposition of:

    (1) Eventide: 391,166

    (2) Kuruvilla: 0

    (3) John: 0

    (iv) Shared power to dispose or to direct the disposition of:

    (1) Eventide: 0

    (2) Kuruvilla: 391,166

    (3) John: 391,166

     
     

    Item 5. Ownership of Five Percent or Less of a Class:

    This statement is being filed to report the fact that as of the date hereof Eventide Asset Management, LLC has ceased to be the beneficial owner of more than five percent of the Issuer’s outstanding Common Stock.

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:

    Not Applicable

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company:

    Not Applicable

    Item 8. Identification and Classification of Members of the Group:

    Not Applicable

    Item 9. Notice of Dissolution of Group:

    Not Applicable

    Item 10. Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

     
     

    SIGNATURES

     

    The undersigned certify, after reasonable inquiry and to the best knowledge and belief of the undersigned, that the information set forth in this Statement is true, complete and correct. The undersigned agree to the filing of this single Statement on Schedule 13G.

     

    Eventide Asset Management, LLC

    Date: November 11, 2024

    By: /s/ Peter J. Luiso

    Name: Peter J. Luiso

    Title: General Counsel

     

     

    Finny Kuruvilla, M.D., Ph. D.

    Date: November 11, 2024

    By: /s/ Finny Kuruvilla, M.D., Ph. D.

    Name: Finny Kuruvilla, M.D., Ph. D.

    Robin C. John

    Date: November 11, 2024

    By: /s/ Robin C. John

    Name: Robin C. John

     
     

     

    EXHIBIT 1

    WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto is filed on behalf of each of them;

    NOW, THEREFORE, the parties hereto agree as follows:

    Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph. D. and Robin C. John do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file a Statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Statement on Schedule 13G shall be filed on behalf of each of them.

    Eventide Asset Management, LLC

    Date: November 11, 2024

    By: /s/ Peter J. Luiso

    Name: Peter J. Luiso

    Title: General Counsel

     

     

    Finny Kuruvilla, M.D., Ph. D.

    Date: November 11, 2024

    By: /s/ Finny Kuruvilla, M.D., Ph. D.

    Name: Finny Kuruvilla, M.D., Ph. D.

    Robin C. John

    Date: November 11, 2024

    By: /s/ Robin C. John

    Name: Robin C. John

    Get the next $KRRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KRRO

    DatePrice TargetRatingAnalyst
    4/29/2025$74.00Overweight
    Cantor Fitzgerald
    4/16/2025$25.00Buy
    Chardan Capital Markets
    1/10/2025$155.00Outperform
    Oppenheimer
    10/21/2024$153.00Strong Buy
    Raymond James
    8/14/2024$180.00Outperform
    William Blair
    3/28/2024$100.00 → $115.00Buy
    H.C. Wainwright
    2/27/2024$120.00Outperform
    BMO Capital Markets
    12/4/2023$100.00Buy
    H.C. Wainwright
    More analyst ratings

    $KRRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

      SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

      11/14/24 7:54:42 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

      SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

      11/14/24 3:04:22 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

      SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

      11/14/24 12:21:08 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Korro Bio with a new price target

      Cantor Fitzgerald initiated coverage of Korro Bio with a rating of Overweight and set a new price target of $74.00

      4/29/25 8:10:45 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital Markets initiated coverage on Korro Bio with a new price target

      Chardan Capital Markets initiated coverage of Korro Bio with a rating of Buy and set a new price target of $25.00

      4/16/25 9:07:30 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Korro Bio with a new price target

      Oppenheimer initiated coverage of Korro Bio with a rating of Outperform and set a new price target of $155.00

      1/10/25 8:59:40 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Korro Bio Inc.

      10-Q - Korro Bio, Inc. (0001703647) (Filer)

      5/7/25 4:40:22 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

      8-K - Korro Bio, Inc. (0001703647) (Filer)

      5/7/25 4:35:10 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Korro Bio Inc.

      DEFA14A - Korro Bio, Inc. (0001703647) (Filer)

      4/29/25 6:06:51 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mathers Edward T bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      4/24/24 5:00:19 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Florence Anthony A. Jr. bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      4/24/24 5:00:26 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Yang Rick bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      4/24/24 5:00:16 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Scientific Officer Vincent Loic A

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      4/1/25 9:46:16 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Senior Vice President, Finance Dolan Oliver

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      4/1/25 9:46:19 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Vincent Loic A

      3 - Korro Bio, Inc. (0001703647) (Issuer)

      4/1/25 9:43:14 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

      CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company's Chief Scientific Officer. "We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy," said Ram Aiyar, Ph.D., CEO and President of Korro. "He joins us at an important time as we advance multiple candidates i

      4/1/25 7:30:00 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

      CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

      12/10/24 8:00:00 AM ET
      $CAMP
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

      - Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team - Partnered with Novo Nordisk to develop up to two targets for cardiometabolic diseases leveraging Korro's proprietary OPERATM platform - Ended third quarter of 2024 with $169.1 million in cash, cash equivalents and marketable securities - Cash runway into the second half of 2026 expected to fund KRRO-110 through completion of a Phase 1/2 clinical study and progress additional pipeline candidates CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ko

      11/12/24 4:05:00 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Korro to Participate in Upcoming Investor Conferences

      CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) today announced that members of management will participate in the following upcoming investor conferences: 2025 RBC Capital Markets Global Healthcare ConferenceRam Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Wednesday, May 21, 2025, at 2:35 p.m. ET. Jefferies Global Healthcare Conference Dr. Aiyar and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will present on Wednesday, June 4, 2025, at 9:55 a.m. ET. Goldman Sachs 46th Annual Global Healthcare Conference Dr. Aiyar and Dr. Olugemo, will present on Monday, June 9, 2025, at 4:00 p.m. ET. A live webc

      5/14/25 4:05:00 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

      —Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) on track for the second half of 2025  —Streamlining operations and focusing on delivering potential value generating program milestones, with workforce reduction of approximately 20% and cost reductions expected to extend cash runway into 2027   —Second development candidate expected to be announced in 2025  —Ended first quarter 2025 with $139.0 million in cash, cash equivalents and marketable securities     CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of gene

      5/7/25 4:30:00 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

      CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company's Chief Scientific Officer. "We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy," said Ram Aiyar, Ph.D., CEO and President of Korro. "He joins us at an important time as we advance multiple candidates i

      4/1/25 7:30:00 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care